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Abstract In this paper we show that the only known Na+
dependent transporter of carnitine in mammals, organic cation
transporter number 2 (OCTN2), is subject to differential
splicing. Cloning of OCTN2 in different rat tissues identified
two splicing variants. We have developed a real time quantitative
polymerase chain reaction method for quantification of these
splice variants. Both splice variants could be detected in all
tissues examined with a relative abundance of 0.1^1% of the full
length transcript. We also draw attention to the previously
described mutations in clinical examples of primary carnitine
deficiency in humans where the described mutations appear to be
those of a splicing or mis-splicing event. ß 2001 Federation of
European Biochemical Societies. Published by Elsevier Science
B.V. All rights reserved.
Key words: Systemic carnitine de¢ciency;
Real time quantitative PCR (TaqMan); Splice variants;
Organic cation transporter; Carnitine
1. Introduction
Novel organic cation transporter number two (OCTN2), is
the only known sodium co-transporter of carnitine, an essen-
tial component of long chain fatty acid transport into the
mitochondrial matrix for oxidation. As omnivores, we rely
on a dietary intake of approximately 70% of our daily require-
ments for carnitine. Uptake, biosynthesis and renal reabsorp-
tion are all vital components of a not yet well understood
balance of carnitine in our bodies, where the distribution of
plasma carnitine into tissues plays an important role. Tissue
concentrations of carnitine vary over a wide range with the
highest local concentrations in humans found in skeletal
muscle and heart (3^5 mM) [1]. However in other animal
tissues, concentrations of carnitine have been described as
high as 2000 fold that of plasma [2], reaching concentrations
of up to 50 mM in the caudal epididymis of rats. This mosaic
of tissue carnitine stores illustrates the important role played
by active carnitine transporter protein(s) in mammals.
The kinetics of carnitine transport di¡er from tissue to tis-
sue and are even variable within the one tissue type showing
both high and low a⁄nities for carnitine (muscle [3,4] ; kidney
[5]; and liver [6,7]). Over-expression of the OCTN2 protein in
cultured cells has demonstrated that this transporter has a
high a⁄nity for carnitine, and its kinetics of transport are
consistent with some of those found in whole tissues [8^10].
In fact, patients with systemic carnitine de¢ciency (SCD), an
hereditary disease associated with myopathy, muscle and met-
abolic disorders, have now been shown de¢nitively to carry
mutations in their OCTN2 genes.
The mutations described so far for these patients have been
mostly point mutations [10^19], with only one publication [20]
describing mutations at the level of transcription; a deletion
and a partial intronic insertion. In a further report from Bur-
winkel et al. [21] a nonsense mutation in exon V is described
as being the cause of the observed carnitine de¢ciency, how-
ever it was noted that in the two unrelated patients there was
an associated splicing abnormality at the intron VI/exon VII
boundary. The novel transcript was identi¢ed by reverse tran-
scription-polymerase chain reaction (RT-PCR) but despite ex-
tensive sequencing, the researchers could ¢nd no causal alter-
ation of the genomic DNA in the vicinity of the splice
boundary, compatible with abnormal splicing.
The rat OCTN2 gene shares 87% sequence homology with
the human cDNA sequence, and 85% amino acid similarity
[22], its kinetics of transport mimic those of the Na depen-
dent transporter in humans except for a slight substrate im-
partiality between carnitine and the more general cation TEA
[8]. In the process of cloning the rat OCTN2 gene for further
study we observed a number of di¡erent mRNA transcripts
indicating possible di¡erential splicing of this gene in rats. We
analysed these transcripts using quantitative real time PCR in
di¡erent rat tissues and discuss our ¢ndings in relation to the
mutations reported for this gene in humans.
2. Materials and methods
2.1. Preparation of RNA/initial cloning
Three healthy male Sprague^Dawley rats were killed by decapita-
tion. Liver, heart, kidney, testis, small intestine and skeletal muscle
from the hind limb were excised and immediately frozen in liquid
nitrogen until further use. Total RNA was isolated from 30 mg frozen
tissue using Qiagen mini-prep columns (Qiagen AG, Basel, Switzer-
land) according to the manufacturer’s instructions. An additional pro-
teinase K treatment (Promega, Madison, WI, USA) of 6 U (10 min at
55‡C) was needed prior to isolation of RNA from skeletal muscle and
heart.
cDNA was made by reverse transcribing 5 Wg total RNA using the
enzyme SuperscriptII (Life Technologies AG, Basel, Switzerland) and
random hexamer primers (Microsynth, Switzerland) according to the
manufacturer’s directions. DNase treatment was deemed unnecessary
for quantitative PCR as the amplicons for GAPDH and OCTN2 span
intron/exon boundaries and genomic DNA contaminants would not
amplify under the limiting thermocycling conditions used. Initial clon-
ing of rat OCTN2 was of a PCR product ampli¢ed with forward
primer 5P-GGCATGCGGGACTACGACGA and degenerate reverse
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primer 5P-RGYGKCCCTRGAGGAAGGTG cloned into the vector
pCR-2.1 (Invitrogen, The Netherlands).
Sequencing of OCTN2 clones was done by Microsynth (Switzer-
land), single strand sequencing in four overlapping segments using
two vector and two internal sequencing primers.
2.2. OCTN2 mRNA quantitation
Real time quantitative PCR (TaqMan, Applied biosystems, Rot-
kreuz, Switzerland) was performed on an ABI PRISM 7700 sequence
detector to determine the relative expression levels of the various
splice variants observed in rat tissues (see Fig. 1).
Primer pairs were chosen with a constant forward primer, a FAM/
TAMRA modi¢ed oligo as the reporter probe, and a variable reverse
primer which, by design, was the crucial determining factor in ampli-
fying the di¡erent transcripts. This primer was placed across the exon/
exon boundary amplifying only that transcript which corresponded to
one of those we had observed through our sequencing results.
The forward primer 5P-TGGGAGTACAACAAGGACGACGTC-
TT-3P (bp 348^371, where 1 is the start codon ATG), non-coding
strand probe 5P-TCCCGAAATGAAGGAGCCCATCA-3P (bp 483^
461), primer B-full length transcript 5P-ACATTCTTGCGACCAAA-
CCTG-3P (bp 515^495), primer B-exon III deletion 5P-TTGAAA-
GAATTTCTGTTCCTG-3P (bp 671^652+497^495) and primer B-
88del 5P-GCAGCATCCTCCAGTCTCTGTC-3P (bp 778^761+497^
493) were used.
For each reverse primer, the ¢nal 3^5 nucleotides (3P-end) corre-
sponded always to the last portion of exon II. Internal control glyc-
eraldehyde-3-phosphate dehydrogenase (GAPDH) used previously
published primers and probe [23]. cDNA corresponding to 25 ng of
reverse transcribed total RNA was ampli¢ed in a 25 Wl volume reac-
tion using TaqMan universal PCR Mastermix (PE biosystems) in
triplicate assays for both rOCTN2 targets and the endogenous control
GAPDH. Primers (Microsynth, Switzerland) were used at a concen-
tration of 300 nM each, FAM/TAMRA £uorophore/quencher report-
er probe (Eurogentec, Belgium) at a concentration of 100 nM. Ther-
mocycling conditions were as for standard TaqMan protocol (PE
biosystems), 10 min denaturation at 95‡C followed by 40 cycles of
95‡C for 15 s, 60‡C for 60 s.
The primers and probe were validated for ampli¢cation e⁄ciency
by running the reaction at ¢ve di¡erent dilutions of template and
subtracting the results obtained for the control GAPDH from those
of the target, this established that the ampli¢cation e⁄ciency was the
same for all primer pairs. Thereafter, analysis of the results obtained
was based on the Ct method of calculation, where Ct is the cycle
number at which the £uorescence of the sample crosses a given thresh-
old. This threshold is set within the linear log phase of each reaction,
i.e. where ampli¢cation of the product is still exponential and there-
fore a direct correlation can be made with the relative amounts of
starting template in each reaction.
For more information see the web site of Applied Biosystems at the
following address http://www.appliedbiosystems.com/molecularbiol-
ogy/about/pcr/sds/5700_sds/5700app.html#section2.
The expression levels of the full length carnitine transporter in the
liver was arbitrarily taken as the ‘calibrator’ for all calculations and
all other tissues were normalised accordingly. Results are given as
expression of each transcript relative to the full length in liver þ S.D.
for each tissue of three animals.
2.3. Computer analysis
Prediction of protein tertiary structure was performed with the on-
line-server HMMTOP prediction of transmembrane helices and topol-
ogy of proteins version 1.1 [24] and Prosite databases (SIB, Geneva,
Switzerland version 99.07) [25].
3. Results/discussion
The rat carnitine transporter OCTN2 was ampli¢ed by
PCR from liver, kidney and muscle tissues as described in
Section 2 and cloned into PCR TOPO cloning vector pCR-
2.1. Screening of the resultant clones showed the presence in
all tissues of shorter than expected inserts (roughly one in 10
clones screened). Sequencing of the clones revealed three dis-
tinct forms of cDNA. Aside from the full length published rat
OCTN2 a second transcript was obtained from the clones
derived from liver RNA which we termed ‘88del’ and a third
termed ‘exon III’ from both muscle and kidney clones (see
Fig. 2).
Comparison with the human OCTN2 genomic sequence
from the database [26] (the rat genomic not being available
to date but sharing a 87% cDNA sequence homology) re-
vealed exon III to be a product of splicing where, as its
name suggests, the whole of exon III was spliced out resulting
in a predicted truncated protein of 226 amino acids. The sec-
ond, termed 88del for what would be a deletion of 88 amino
acids in any translated product, was missing exon III and a
part of exon IV, the sequence resuming in the middle of exon
IV at a cryptic splice site. At this point in the cDNA the rat
sequence varies from that of the human genomic sequence, a c
to a base pair di¡erence changing a ccg motif into a cag
potential splicing signal. It is at this dimorphism in a normal
rat that the resumption of the transcript partway through
exon IV is resumed encoding a predicted protein of 469 amino
acids (see Fig. 3). In a normal transcript, where all 10 exons
are included, this cryptic splice site in the middle of exon IV
would go unnoticed. It is only when exon IV is spliced out
that it is presented as a false intron acceptor site and coding
resumes partway through the exon.
A strategy was derived whereby we could check the abun-
dance of these splice variants in relation to the full length
sequence and whether or not the variants were tissue speci¢c.
Previously published studies on the mRNA expression of
OCTN2 have consisted solely of Northern blot analysis using
a probe randomly primed o¡ the entire or a large (s 900 bp)
part of the mRNA and therefore retain inherent problems of
questionable speci¢city given the large degree of sequence ho-
Fig. 1. Schematic illustration of the strategy employed for quantitative PCR of the di¡erent mRNA transcripts from the rat OCTN2 gene de-
picting the location of forward and reverse primers and the position of the modi¢ed oligonucleotide reporter probe.
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mology shared by the known members of this expanding fam-
ily of transporters. Doublet bands have been previously noted
in Northern blot analysis of both human and rat OCTN2
[26,22,32] but their true identity remained uncharacterised.
To avoid these problems of high family homology we chose
the method of quantitative PCR and developed a strategy
whereby we could speci¢cally target each chosen mRNA spe-
cies for individual ampli¢cation and analysis.
Fig. 2. cDNA alignment of sequences obtained for the full length rat OCTN2 and the two splice variants. Arrows signify positions of introns
as derived from the human genomic sequence. The precise boundary between intron and exon was taken always with a cag or tag consensus
donor site as the last 3 bp of the intron, thus de¢ning the ¢rst base of the following exon.
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Using always the same forward primer and reporter probe
we could vary the reverse primer to amplify only one speci¢c
transcript at a time. For the exon III reverse primer, only
when exon III is completely spliced out and the start of
exon IV joined to exon II can the primer anneal and tran-
scription start. For the reverse primer 388del the same is true
only for when exon III and part of exon IV are skipped and
the primer can span the gap and serve as the initiation of
transcription. The expression levels of each target cDNA
was standardised ¢rst for each sample by the subtraction of
the internal GAPDH standard and then made relative to each
other by arbitrarily designating the full length transcript in
liver as having 100% expression of the gene and all the others
expressed as a percentage thereof. The e⁄ciency of ampli¢ca-
tion was checked for all targets by performing a series of serial
dilutions of template for each primer pair. The resulting quan-
titative PCR told us very clearly that OCTN2 was most abun-
dant in the testis of rat, followed by liver and kidney tissues,
however the heart and skeletal muscle, where carnitine con-
centrations are at their highest in humans, showed negligible
amounts of OCTN2 transcript, neither full length nor either
of the two variants (see Fig. 4). These results for the full
length rat OCTN2 mRNA were well in accordance with the
original data observed by Northern analysis when this trans-
porter was ¢rst cloned by Sekine et al. [22]. Rat testis, next to
epididymis, one of the highest carnitine storing tissues in ro-
dents [2,1], showed the most signi¢cant amounts of both full
length and variant mRNA’s. Carnitine has long been shown
to have a physiologically important role to play in the testis.
It’s high concentrations correlate directly with sperm matura-
tion (as determined by motility and fertility) as they progress
along the seminiferous tubules to the epididymis [27^31].
In all tissues tested, both splice variants could be detected
and ampli¢ed with direct correlation to the level of starting
template, though in low amounts relative to that of the full
length sequence (Fig. 4). Again, only in testis was a signi¢cant
level of expression detected for either of the splicing variants.
The 88del variant, although accounting for only 1% of the
total coding sequence showed a 10-fold higher level of expres-
sion than the other exon III variant, and two- to three-fold
higher than that of the full length coding sequence found in
low-expressing tissues such as heart and skeletal muscle.
Analysis of the predicted amino acid sequence [24,25] of the
88del splice variant reveals a protein with intact N and C
termini with correct cytosolic orientation but missing four
putative transmembrane domains after the extracellular loop
(Fig. 5). The sugar transport signature is disrupted in both
variants, sitting as it is on the exon II/III boundary. The exon
III deletion, however, leaves a largely disrupted sequence,
prematurely terminating the protein after the ¢rst two puta-
Fig. 3. Predicted amino acid sequence alignment of full length rat rOCTN2, the two splice variants reported in this study, human full length
hOCTN2 and the exon IV splice mutation [20].
Fig. 4. Levels of mRNA transcripts in six di¡erent tissues of three
rats were assessed for both the full length OCTN2 and both of the
di¡erentially spliced variants. Results were compiled from three ani-
mals, error is given as þ S.D.
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tive transmembrane domains. The big extracellular loop re-
mains with its glycosylation sites, along with two potential
protein kinase C and one casein kinase 2 phosphorylation
sites, and three out of seven myristolation sites still intact,
indicating the potential to be still active depending on the
mechanism of phosphorylation. However, the protein is minus
its potentially important cAMP site and is only half the size of
the parent transcript.
The splice variant 88del is missing 88 amino acids in the
middle of the protein e¡ectively omitting one third of its
transmembrane segments. Unlike the exon III variant, it re-
sumes its coding sequence in the original frame and so retains
most of the C-terminal part of the protein and the inherent
signature motifs including the cAMP phosphorylation site.
However, similar to the exon III deletion, it has also lost its
sugar motif and its amidation site.
The substrate binding sites of this Na co-transporter of
carnitine are unknown but the presence of four highly con-
served cysteine residues within the N-terminal extracellular
loop amongst all members of this family, and in some cases
those of the anion transporter family as well, would indicate
it’s tertiary structure plays some functional role and its extra-
cellular orientation would make it a likely candidate for the
position of substrate recognition and/or binding. Retention of
this loop but loss of any activation domains in a shortened
version of the full length transporter, could play a role in
regulation of transport by competition of the active and in-
active forms at the cell surface. It would be of interest to note
whether these variants are upregulated in response to altered
extracellular carnitine levels.
A mutant transcript has been described in a patient with
SCD in which exon IV has been deleted. Similar to our exon
III, this leads to a resumption of an out-of-frame code and
premature termination of the protein at 237 residues (19 ami-
no acids after the splice site). Importantly for this splice mu-
tation, the human amino acid sequence unlike the rat encodes
an ATP/GTP binding motif at exactly this exon III/IV bound-
ary. One amino acid di¡erence in the rat renders this motif
unrecognisable to a prediction server [25] as a potentially
functional ATP/GTP binding domain. This would imply
that the two proteins are most likely activated by di¡erent
mechanisms of phosphorylation. Initial work by two inde-
pendent research groups on human OCTN2 mRNA showed
the presence of a double band in a Northern blot of adult
kidney mRNA (absent in proximal tubules) [32,26] that was
not detected in that of rat. Perhaps more relevant to this
study, a second smaller transcript in the testis of rat was
demonstrated by Northern blot in the original work which
¢rst cloned the gene [22].
In the observed cases to date for humans with SCD, there
exist so far three known alterations of the splicing in
hOCTN2.
One is clearly a mis-splicing event, a 19 bp intronic inser-
tion which in turn, led to a frame shift and consequently a
premature termination of the coding sequence. The second, as
described by the same authors [20], is a clean exon IV dele-
tion, though it was not described as such. Here, as in the
intronic insertion above, the mis-splicing occurred before the
premature stop, which resulted from the shift in the frame of
the coding sequence. It should be mentioned that neither of
these cases is appropriate to the mechanism of nonsense asso-
ciated mRNA decay.
Nonsense associated alternative splicing (NAS) is part of
the process of nonsense mediated mRNA decay (NMD)
Fig. 5. Pictographical depiction of the protein products of all splice variants. ‘ = ’ depicts possible interactions between N-terminal cysteine resi-
dues, highly conserved within the cation and anion transporter families.
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which can involve both exon skipping and more often, intron
retention. NMD, is thought to be a mechanism by which cells
can eliminate imperfect mRNAs, which would lead to the
translation of potentially harmful or toxic proteins.
The hallmark of NMD has been the reduction in abun-
dance of the mRNA associated with a premature termination
codon (PTC). In cases of NAS, the splicing occurs immedi-
ately after a PTC and is thought to provide a signal to medi-
ate the rapid decay of the transcript.
The third case of mis-splicing reported for human OCTN2
was in a paper by Burwinkle et al. [21] who observed a PTC in
exon V and then a skipping of exon VII in two unrelated
German patients with SCD. One was heterozygous and both
full length and shortened transcripts were observed, the ho-
mozygous RT-PCR produced only the shortened transcript. It
was not indicated if any reduction in abundance of either
transcript was observed, which would be indicative of
NMD. However it is possible that what they observed was
NAS, although the to-date speculated mechanism behind
NAS would preclude the presence of the intervening exon
VI, which came between the observed splice and the PTC.
In all other cases of NMD/NAS observed so far the next
exon/exon boundary is a¡ected and seems to show a ‘position-
al bias’ i.e. if the PTC is within 50 bp 5P of the exon bound-
ary, in which case sometimes consecutive exons can be
skipped [33^35].
OCTN2, in both humans and rats is clearly subject to splic-
ing events. Here, we show the presence of two splicing var-
iants in normal healthy male Sprague^Dawley rats.
We feel it is important to stress that we have not attempted
to account for all splice variants of OCTN2, merely to point
out that they exist for this gene and examine the abundance of
those we knew existed. We think this would be interesting to
follow up, especially in light of potential human splicing/mis-
splicing events observed in patients with primary SCD.
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